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We characterized 16 additional mutations in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase
(RT) whose role in drug resistance is still unknown by analyzing 1,906 plasma-derived HIV-1 subtype B pol
sequences from 551 drug-naı¨ve patients and 1,355 nucleoside RT inhibitor (NRTI)-treated patients. Twelve muta-
tions positively associated with NRTI treatment strongly correlated both in pairs and in clusters with known NRTI
resistance mutations on divergent evolutionary pathways. In particular, T39A, K43E/Q, K122E, E203K, and H208Y
clustered with the nucleoside analogue mutation 1 cluster (NAM1; M41LL210WT215Y). Their copresence in
this cluster was associated with an increase in thymidine analogue resistance. Moreover, treatment failure in the
presence of K43E, K122E, or H208Y was significantly associated with higher viremia and lower CD4 cell count.
Differently, D218E clustered with the NAM2 pathway (D67NK70RK219QT215F), and its presence in this
cluster determined an increase in zidovudine resistance. In contrast, three mutations (V35I, I50V, and R83K)
negatively associated with NRTI treatment showed negative correlations with NRTI resistance mutations and were
associated with increased susceptibility to specific NRTIs. In particular, I50V negatively correlated with the
lamivudine-selected mutation M184V and was associated with a decrease in M184V/lamivudine resistance, whereas
R83K negatively correlated with both NAM1 and NAM2 clusters and was associated with a decrease in thymidine
analogue resistance. Finally, the association pattern of the F214L polymorphism revealed its propensity for the
NAM2 pathway and its strong negative association with the NAM1 pathway. Our study provides evidence of novel
RT mutational patterns that regulate positively and/or negatively NRTI resistance and strongly suggests that other
mutations beyond those currently known to confer resistance should be considered for improved prediction of
clinical response to antiretroviral drugs.
During its spread among humans, human immunodeficiency
virus type 1 (HIV-1) has developed an extraordinary degree of
genetic diversity, mainly due to the intrinsic inability of HIV-1
reverse transcriptase (RT) to carry out proofreading of DNA
during replication (21) and exacerbated by the high rate of
viral replication in vivo (109 viral particles produced daily).
Among the different areas of the viral genome, the pol gene,
encoding enzymes such as reverse transcriptase and protease,
is subjected not only to natural evolutionary forces but also to
selective pressure imposed by pharmacological treatment (9,
10, 16, 36).
The HIV-1 reverse transcriptase enzyme is responsible for
the conversion of the single-stranded RNA genome into a
double-stranded DNA that is later integrated into host
genomic DNA (14, 43). Owing to its pivotal role in the HIV-1
life cycle, the reverse transcriptase represents an attractive
target for antiviral therapy. To date, 11 out of 21 compounds
approved for the treatment of HIV-1 infection are reverse
transcriptase inhibitors. In particular, they consist of the group
of seven nucleoside analogue reverse transcriptase inhibitors
(NRTIs; zidovudine, stavudine, lamivudine, didanosine, aba-
cavir, zalcitabine, and emtricitabine), one acyclic nucleoside
monophosphate (tenofovir, generally considered in the class of
NRTIs), and three nonnucleoside analogue reverse transcrip-
tase inhibitors (NNRTIs; nevirapine, efavirenz, and delavirdine)
(2, 9, 11, 28).
When antiviral therapy fails to be fully suppressive, new viral
variants can emerge, allowing HIV-1 to escape from reverse
transcriptase inhibitors by accumulating mutations, either
alone or in multiple clusters, that affect the long-term therapy
targeting reverse transcriptase (3, 13, 20, 35). To date, two
mechanisms are known to contribute to decreased NRTI sus-
ceptibility (9, 26). Several mutations or groups of mutations in
HIV-1 reverse transcriptase can promote resistance by selec-
tively impairing the ability of the enzyme to incorporate the
nucleoside analogue into DNA. These mutations include
M184V, K65R, and L74V and the Q151M complex (A62V,
V75I, F77L, F116Y, and Q151M) (33, 36, 42). On the other
hand, a specific set of mutations collectively termed “nucleo-
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side analogue mutations” (NAMs; M41L, D67N, K70R, L210W,
T215Y, and K219E/Q) can confer resistance by promoting a
phosphorolysis reaction that selectively removes the nucleoside
analogue from the terminated DNA chain (1, 22, 24). The NAMs
occur gradually under the selection pressure imposed by the thy-
midine analogues (zidovudine and stavudine) and can promote
resistance to almost all nucleoside and nucleotide analogues. Re-
cent studies have suggested the existence of two distinct pathways
of NAM resistance, defined by different mutation patterns
(NAMs 1 [M41L, L210W, and T215Y] and NAMs 2 [D67N,
K70R, and K219Q/E]), whose evolution seems to be strictly in-
fluenced by viral replication (15, 44). On the other hand, resis-
tance to NNRTIs is mediated by the appearance of mutations at
the hydrophobic NNRTI binding pocket that reduce the affinity
of the inhibitor for the enzyme (9, 36).
To date, mutations at 61 residues in HIV-1 reverse trans-
criptase have been related to treatment with the experimen-
tally tested reverse transcriptase inhibitors. Of these, 18
sites are involved in resistance to the eight currently ap-
proved NRTIs and 16 sites are involved in resistance to the
three currently approved NNRTIs (20; Stanford HIV Drug
Resistance Database, http://hivdb.stanford.edu).
Since resistance to reverse transcriptase inhibitors is a very
complex phenomenon, it is conceivable that more mutations
(and associations of mutations) than currently known are in-
volved in the development of drug resistance and therefore
lead to therapeutic failure. For instance, recent studies have
identified novel positions or mutations positively associated
with NRTI treatment (7, 8, 13); however, their exact role in the
development of NRTI resistance remains unclear. Thus, we
focused our attention on 16 uncharacterized mutations in
HIV-1 reverse transcriptase and used computational and sta-
tistical methods to define their association with specific NRTIs
and NRTI resistance mutations at therapeutic failure. A better
definition of the mutational pathways that regulate the evolu-
tion of drug resistance in vivo is a key element for the design
of effective anti-HIV chemotherapy. Moreover, our study un-
derlines the importance of computational methods as impor-
tant tools for the interpretation of HIV genetic variability and
suggests that additional mutations beyond those currently
known to be associated with NRTI resistance should be con-
sidered to define precise algorithms able to predict resistance
to antiretroviral drugs.
MATERIALS AND METHODS
Patients. The study included 1,906 patients enrolled either in the Italian
Cohort of Antiretroviral-Naı¨ve (ICONA) patient study or in different clinical
centers in central Italy. Five hundred fifty-one patients were naı¨ve for treatment
with antiretroviral drugs, and 1,355 were failing their last antiretroviral regimen
containing at least one NRTI (865 were failing NRTIs but not NNRTIs, and 490
were failing NRTIs plus NNRTIs). Drug-naı¨ve patients underwent genotypic
tests between January 1997 and July 2004, while NRTI-treated patients were
tested between January 1998 and July 2004. Overall, drug-treated patients were
exposed to an average of four NRTIs and 1,271 (93.8%) were receiving highly
active antiretroviral therapy. In detail, 84.2% of patients had been treated with
lamivudine, 73.6% with zidovudine, 70.7% with stavudine, 60.0% with di-
danosine, 21.7% with abacavir, 15.3% with zalcitabine, and 10.5% with tenofovir.
At the time of genotypic analysis, 64.9% of patients were receiving treatment
with lamivudine (with a median time of 450 days), 48.1% with stavudine (median
time, 492 days), 34.5% with zidovudine (median time, 436 days), 33.2% with
didanosine (median time, 393 days), 12.5% with abacavir (median time, 363
days), 7.2% with tenofovir (median time, 221 days), and 2.7% with zalcitabine
(median time, 359 days). Patients carrying non-B subtypes of HIV pol were
excluded from this analysis. Data for all patients were stored in a specifically
designed anonymous database that included mutational, demographic, immuno-
logic, virologic, and therapeutic parameters.
HIV sequencing. HIV genotype analysis was performed on plasma samples by
means of a commercially available kit (ViroSeq HIV-1 genotyping system; Ab-
bott Laboratories) (6, 29). Briefly, RNA was extracted, retrotranscribed by mu-
rine leukemia virus RT, and amplified with Amplitaq-Gold polymerase enzyme
by using two different sequence-specific primers for 40 cycles. Pol-amplified
products (containing the entire protease and the first 335 amino acids of the
reverse transcriptase open reading frame) were full-length sequenced in sense
and antisense orientations by an automated sequencer (ABI 3100) by using seven
different overlapping sequence-specific primers (6, 29). Sequences having a mix-
ture of wild-type and mutant residues at single positions were considered to have
the mutant(s) at that position. The isolates were subtyped by comparing them to
reference sequences of known subtype (http://hivdb.stanford.edu). The majority
of nucleotide sequences from drug-naı¨ve and NRTI-treated patients treated with
at least one protease inhibitor within the highly active antiretroviral therapy
regimen have already been submitted to GenBank (6, 29, 41), and more recently
622 sequences from NRTI-treated and drug-naı¨ve patients have been submitted
(see below).
Statistical analysis. (i) Mutation prevalence. To assess the association of
reverse transcriptase mutations with NRTI treatment, we calculated their re-
spective frequencies in isolates from 551 drug-naı¨ve patients, 865 patients failing
their last antiretroviral regimen containing NRTIs but not NNRTIs, and 490
patients failing their last antiretroviral regimen containing NRTIs plus NNRTIs.
We then performed chi-squared tests of independence (based on a 2  2
contingency table) to verify statistically significant differences in frequency be-
tween the following groups of patients: (i) drug-naı¨ve patients versus NRTI- but
not NNRTI-treated patients, (ii) drug-naı¨ve patients versus NRTI-plus-NNRTI-
treated patients, and (iii) NRTI- but not NNRTI-treated patients versus NRTI-
plus-NNRTI-treated patients.
We focused our attention on 16 mutations (K20R, V35I, V35M, T39A, K43E,
K43N, K43Q, I50V, R83K, K122E, G196E, E203D, E203K, H208Y, F214L, and
D218E), to which we refer as novel mutations henceforth, as they have not yet
been reported to be associated with NRTI resistance by the Stanford HIV Drug
Resistance Database (http://hivdb.stanford.edu) and by the International AIDS
Society (20).
To assess the association of each novel mutation with treatment with a specific
NRTI, we compared the rate of occurrence of each novel mutation in the
subpopulation that underwent treatment with a specific NRTI with that in the
subpopulation that did not undergo treatment with that NRTI; we then per-
formed chi-squared tests of independence to verify statistically significant differ-
ences (P  0.05).
In our analysis, the Cochran rule, which is a conventional criterion for the
chi-squared test to be valid, was fully satisfied. In fact, in each contingency table
performed with our data set, 80% of the expected frequencies exceed 5, and all
the expected frequencies exceed 1. In addition, in those few cases where the
expected frequency in a single cell of the contingency table was less than 5, the
significance was also confirmed by using the Monte Carlo significance test pro-
cedure (17).
We used the Benjamini-Hochberg method (5) to identify results that were
statistically significant in the presence of multiple-hypothesis testing. A false
discovery rate of 0.05 was used to determine statistical significance. This analysis
was performed on the subset of 865 patients failing an antiretroviral regimen
containing NRTIs but not NNRTIs.
To assess the association of novel reverse transcriptase mutations with viremia
and CD4 cell count, we compared viremia and CD4 cell count values of patients
harboring isolates with a specific novel mutation with those of patients harboring
isolates without that novel mutation. Viremia and CD4 cell count values ana-
lyzed were concomitant with the genotype resistance testing (30 days).
To verify statistically significant differences, the median test was performed,
and the Benjamini-Hochberg method was used to correct for multiple-hypothesis
testing. A false discovery rate of 0.05 was used to determine statistical signifi-
cance.
(ii) Mutation covariation. In the set of 1,355 NRTI-treated patients, we ex-
haustively analyzed patterns of pairwise interactions among mutations associated
with NRTI treatment, including the 16 novel mutations. Specifically, for each
pair of mutations and corresponding wild-type residues, Fisher’s exact test was
performed to assess whether co-occurrence of the mutated residues differed
significantly from what would be expected under an independence assumption.
Again, the Benjamini-Hochberg method was used to correct for multiple testing,
here at a false discovery rate of 0.01. Samples having a mixture of two or more
VOL. 80, 2006 CHARACTERIZATION OF NOVEL HIV-1 RT MUTATIONS 7187
 by on Decem
ber 4, 2009 
jvi.asm.org
D
ow
nloaded from
 
mutations at a given pair of positions were ignored in calculating the covariation,
since it is not possible to identify whether these mutations are indeed located in
the same viral genome.
(iii) Cluster analysis. To analyze the covariation structure of mutations in
more detail, we performed average linkage hierarchical agglomerative clustering,
as described elsewhere (38).
Hierarchical clustering methods, which under different names are also widely
used in phylogenetic tree building, rely on a matrix of pairwise dissimilarities
between entities, based on which groups are associated into hierarchical clusters
of decreasingly strong association. As such, it is in the first instance an explorative
and not a predictive tool. Briefly, in average linkage clustering, clusters of
increasing size are formed starting from one-element groups by iteratively join-
ing two clusters with minimum average intercluster distances between pairs of
mutations. The distance between a pair of mutations was derived from the phi
correlation coefficient, which is a measure of the association between two binary
random variables, with 1 and 1 representing maximal positive and negative
association, respectively. This similarity measure was transformed into a distance
by mapping phi  1 to distance 0 and phi  1 to distance 1, with linear
interpolation in between. The distance between different mutations at a single
position was left undefined, as such pairs never co-occur in a single sequence
(except from mixtures) and would lead to distorted dendrograms owing to their
great distance. The resulting partial distance matrix was then used as input for
the clustering algorithm, ignoring undefined distances in computing averages. To
assess the stability of the resulting dendrogram, confidence values for all subtrees
in the dendrogram were computed by 100 replications of the clustering proce-
dure on sequence sets bootstrapped from the original 1,355 sequences (38). For
instance, a bootstrap value of 1 simply means that out of 100 runs, all 100 had
these two mutations (or groups of mutations) most closely linked.
Association with NRTI susceptibility. We analyzed genotype-phenotype cor-
relations from the HIV Stanford Drug Resistance Database (http://hivdb
.stanford.edu) to assess the association of mutations with NRTI susceptibility. In
particular, for each NRTI we compared the median changes in resistance (n-
fold) in relation to sequences with or without specific novel mutations. The
change in resistance (n-fold) was measured by Virco’s Antivirogram assay.
Structural analysis. The X-ray crystallographic coordinates of HIV-1 reverse
transcriptase deposited in the Protein Data Bank (http://www.rcsb.org/PDB/)
with code 1rtd were used for the structural analysis. The feasibility of direct side
chain-side chain interaction between the mutated amino acids (both intrasubunit
and intersubunit) was assessed by means of molecular graphic visualization using
the public domain program PyMol (http://pymol.sourceforge.net/).
Nucleotide sequence accession numbers. The GenBank accession numbers for
622 sequences of NRTI-treated and drug-naı¨ve patients are as follows:
DQ345123 to DQ345278, DQ347967 to DQ348070, DQ369047 to DQ369180,
DQ369219 to DQ369262, and DQ370181 to DQ370306.
RESULTS
Novel reverse transcriptase mutations and their association
with treatment. By evaluating the first 335 amino acids in
reverse transcriptase sequences derived from 551 drug-naı¨ve
and 1,355 NRTI-treated patients (865 failing their last antire-
troviral regimen containing NRTIs but not NNRTIs and 490
failing their last antiretroviral regimen containing NRTIs plus
NNRTIs), we identified and characterized 16 novel reverse
transcriptase mutations.
Fifteen novel mutations were significantly associated with
treatment with NRTIs, based on the assumption that these
mutations occurred with different frequencies in treatment-
naı¨ve subjects and in patients failing NRTI therapy, respec-
tively (38; F. Ceccherini-Silberstein, V. Svicher, T. Sing, M.
Santoro, N. Beerenwinkel, F. Gago, A. Bertoli, F. Forbici,
M. C. Bellocchi, P. Narciso, A. d’Arminio Monforte, A.
Antinori, and C. F. Perno, Abstr. 14th Int. HIV Drug Resist.
FIG. 1. Frequency of novel reverse transcriptase mutations in isolates from drug-naı¨ve patients and in isolates from patients failing their last
antiretroviral regimen containing an NRTI but not an NNRTI and from patients failing their last antiretroviral regimen containing an NRTI plus
an NNRTI. Statistically significant differences were assessed by chi-squared tests of independence. P values were significant at a false discovery rate
of 0.05 following correction for multiple comparison. *, P  0.05; **, P  0.01; ***, P  0.001.
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Workshop, abstr. 96, 2005). These mutations were grouped
into three classes, based on their prevalence in isolates from
treatment-naı¨ve patients (Fig. 1).
Class I included seven mutations (K43E, K43Q, K43N,
E203D, E203K, H208Y, and D218E) that were completely
absent or occurred with a frequency of 0.5% in isolates from
drug-naı¨ve patients and showed a significant increase (P 0.05
to 0.001) in isolates from patients failing NRTIs (with and
without NNRTIs). Significant frequency differences between
the two groups of patients treated with NRTIs with and with-
out NNRTIs were not observed. However, K43E and H208Y
exceeded 5% in frequency only in isolates from patients failing
NRTIs without NNRTIs (7.3% and 6.5%, respectively), while
D218E reached 6.5% prevalence only in isolates from patients
failing NRTIs with NNRTIs.
Class II included five mutations (K20R, V35M, T39A,
K122E, and G196E) already present in isolates from drug-
naı¨ve patients at a frequency of 2.5% but with a significant
increase (P  0.05 to 0.001) in isolates from both groups of
NRTI-treated patients. In particular, K122E occurred at a
frequency of 22.1% in isolates from drug-naı¨ve patients and
reached 30.7% and 37.2% prevalence in patients failing NRTIs
with and without NNRTIs, respectively. Similarly to class I,
statistically significant differences in frequency were not ob-
served between the two groups of NRTI-treated patients.
Interestingly, and unlike the other classes, class III included
three mutations (V35I, I50V, and R83K) that showed a signif-
icant frequency decrease in isolates from NRTI-treated pa-
tients compared to drug-naı¨ve patients. Specifically, I50V sig-
nificantly decreased (P  0.038) from 4.9% to 2.6% and 2.8%
in isolates of patients failing NRTIs without and with NNRTIs,
while V35I and R83K decreased from 22.5% to 15.1% and
11.1% and from 33% to 22.6% and 21.2% in isolates from
patients failing NRTIs without and with NNRTIs, respectively
(P  0.001).
We also included in our study the common polymorphism
F214L, whose frequency remained stable (around 18%) in
isolates from drug-naı¨ve patients and in both groups of NRTI-
treated patients (data not shown).
All class I and class II mutations showed a remarkable in-
crease in frequency in isolates from patients who had experi-
enced more than four NRTIs (Table 1). In particular, for
K20R, V35M, T39A, K43Q, K122E, H208Y, and D218E, the
increase in frequency observed in isolates from patients who
had experienced more than four NRTIs was statistically signif-
icant (P 0.05) not only compared to isolates from drug-naı¨ve
patients but also compared to isolates from patients who had
experienced fewer than three NRTIs. On the other hand, class
III mutations showed a progressive decrease in prevalence
irrespective of an increasing number of NRTIs (Table 1).
Most class I and II mutations were also significantly associ-
ated (P  0.05) with the use of specific NRTIs (Table 1). In
detail, association with the use of one or more specific NRTIs
in the last regimen was found for H208Y (stavudine), D218E
(abacavir), V35M (abacavir and tenofovir), and K122E (teno-
fovir). In addition, H208Y was also associated with a previous
use of abacavir and didanosine; D218E with a previous use of
zidovudine, zalcitabine, and didanosine; V35M with a previous
use of zalcitabine; and K122E with a previous use of stavudine,
while T39A and K43E were specifically associated with previ-
ous use of zalcitabine. In class III, R83K was negatively asso-
ciated with either stavudine or didanosine treatment (Table 1).
None of the other mutations was significantly associated with
treatment with any specific NRTI in our analysis.
TABLE 1. Association of novel reverse transcriptase mutations with NRTI treatment
Novel mutation
Frequency (%) of mutations
Association(s) with NRTIsbNaı¨ve patients
(n  551)
NRTI-experienced patientsa
3 or fewer
(n  448)
4 or more
(n  417)
K43E 0 4.7 8.4 ddC (P  0.011)
K43N 0 1.3 3.6
K43Q 0.2 2.7 6.5*
E203D 0 1.6 3.1
E203K 0 3.1 6.0
H208Y 0.5 3.6 11.3* ABC (P  0.0001); ddI (P  0.005); d4T (P  0.008)
D218E 0.4 2.2 8.6* ABC (P  0.001); ddC (P  0.002); ZDV (P  0.008); ddI (P  0.011)
K20R 9.3 12.9 19.9*
V35M 2.7 4.7 10.3* ddC (P  0.0001); ABC (P  0.0001); TDF (P  0.009)
T39A 4.7 8.3 12.9* ddC (P  0.002)
K122E 22.1 32.8 42.2* d4T (P  0.001); TDF (P  0.01)
G196E 16.2 23.0 28.8
V35I 22.5 14.2 14.2
I50V 4.9 3.8 1.4
R83K 33.0 25.4 19.7 d4Tc (P  0.0001); ddIc (P  0.005)
a The prevalence (percentage) of each novel reverse transcriptase mutation was determined according to the total number of NRTIs to which the 865 patients failing
their last antiretroviral regimen containing NRTIs without NNRTIs had been exposed. Values in boldface indicate statistically significant differences, corrected for
multiple-hypothesis testing by the Benjamini-Hochberg method at a false discovery rate of 0.05, with respect to the results for isolates from drug-naı¨ve patients.
Asterisks indicate statistically significant differences, corrected for multiple-hypothesis testing by the Benjamini-Hochberg method at a false discovery rate of 0.05,
between isolates from patients experienced with three or fewer NRTIs and isolates from patients experienced with four or more NRTIs.
b Statistically significant associations with the use of specific NRTIs are reported. All P values were significant at a false discovery rate of 0.05 following correction
for multiple-hypothesis testing. Associations with the use of specific NRTIs at the time of genotypic resistance testing are in boldface. Abbreviations: ddC, zalcitabine;
ABC, abacavir; ddI, didanosine; d4T, stavudine; ZDV, zidovudine; TDF, tenofovir.
c R83K is negatively associated with the use of stavudine and didanosine. All the other associations of novel mutations with NRTIs are positive.
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TABLE 2. Significantly correlated pairs of mutations
Novel mutation Frequency no. (%)a Correlated mutationb Frequency no. (%)a Covariation frequency (%)c Phi P valued
T39A 155 (11.4) M41L 488 (36.0) 110 (70.9) 0.25 4.9e-19
L210W 297 (21.9) 63 (40.6) 0.19 1.1e-10
T215Y 463 (34.2) 92 (59.3) 0.18 1.7e-10
K43E 79 (5.8) E44A 16 (1.2) 10 (12.6) 0.34 1.5e-11
L210W 297 (21.9) 62 (78.5) 0.33 3.4e-25
V118I 230 (16.9) 44 (55.7) 0.26 5.1e-15
M41L 488 (36.0) 70 (88.6) 0.25 9.3e-20
T215Y 463 (34.2) 68 (86.1) 0.24 2.6e-17
H208Y 89 (6.6) 17 (19.1) 0.17 1.9e-6
V75M 25 (1.8) 8 (10.1) 0.17 2.1e-5
K43N 34 (3.2) L210W 297 (21.9) 27 (79) 0.20 5.2e-10
M41L 488 (36.0) 30 (88.2) 0.18 1.9e-10
V118I 230 (16.9) 17 (50.0) 0.17 3.2e-7
T215Y 463 (34.2) 29 (85.3) 0.16 2.6e-8
K43Q 56 (4.1) L210W 297 (21.9) 43 (76.8) 0.28 1.7e-18
V118I 230 (16.9) 30 (53.6) 0.24 2.0e-12
E44D 123 (9.1) 24 (42.9) 0.24 1.8e-10
M41L 488 (36.0) 49 (87.5) 0.22 6.2e-16
T215Y 463 (34.2) 48 (85.7) 0.22 1.6e-15
H208Y 89 (6.6) 18 (32.1) 0.21 5.6e-8
K219R 37 (2.7) 10 (17.9) 0.19 4.6e-6
D67N 444 (32.8) 40 (71.4) 0.17 5.0e-9
T69D 98 (7.2) 15 (26.8) 0.16 6.0e-6
K122E 475 (35.1) V118I 230 (16.9) 132 (27.8) 0.23 1.7e-16
L210W 297 (21.9) 161 (33.9) 0.22 5.5e-15
M41L 488 (36.0) 228 (48) 0.18 4.9e-11
T69D 98 (7.2) 58 (12.2) 0.16 1.3e-8
E44D 123 (9) 71 (14.9) 0.15 1.0e-7
G196E 330 (24.3) H208Y 89 (6.6) 39 (11.8) 0.16 8.3e-8
D67N 444 (32.8) 148 (44.8) 0.15 3.1e-8
E44D 123 (9) 56 (17.0) 0.15 2.7e-7
E203D 31 (2.3) H208Y 89 (6.6) 11 (35.5) 0.16 2.2e-5
E203K 54 (4.0) H208Y 89 (6.6) 21 (38.9) 0.32 1.9e-14
E44D 123 (9.1) 24 (44.4) 0.27 2.1e-12
V118I 230 (16.9) 30 (55.5) 0.22 1.0e-10
L210W 297 (21.9) 35 (64.8) 0.21 1.3e-11
K219R 37 (2.7) 10 (18.5) 0.20 2.1e-6
M41L 488 (36.0) 40 (74.1) 0.16 5.9e-9
K219N 30 (2.2) 7 (13.0) 0.15 2.8e-4
H208Y 89 (6.6) E44D 123 (9.1) 38 (42.7) 0.35 2.2e-20
L210W 297 (21.9) 71 (79.8) 0.34 2.6e-27
E203K 54 (4.0) 21 (23.6) 0.32 1.8e-14
V118I 230 (16.9) 50 (56.2) 0.31 6.3e-20
M41L 488 (36) 83 (93.3) 0.28 2.4e-24
D67N 444 (32.8) 66 (74.2) 0.25 2.1e-18
T69D 98 (7.2) 24 (27) 0.23 1.9e-10
T215Y 463 (34.2) 71 (79.8) 0.21 1.5e-13
K43Q 56 (4.1) 18 (20.2) 0.21 5.6e-8
K219R 37 (2.7) 12 (13.5) 0.19 1.0 e-6
K43E 79 (5.8) 18 (20.2) 0.17 1.9e-6
E203D 31 (2.3) 11 (12.4) 0.16 2.2e-5
L74I 36 (2.6) 7 (7.9) 0.15 1.1e-4
D218E 78 (5.8) K219Q 207 (15.3) 53 (68) 0.34 6.0e-23
D67N 444 (32.8) 64 (82) 0.27 3.4e-21
K70R 325 (24.0) 56 (71.8) 0.23 2.0e-13
L74I 36 (2.6) 55 (70.5) 0.23 5.9e-8
T215F 134 (9.9) 25 (32.0) 0.18 1.7e-7
V35I 186 (13.7) R83K 301 (22.2) 69 (37.1) 0.17 1.2e-08
I50V 37 (2.7) M184V 794 (58.6) 14 (37.8) 0.07 6.6e-3
R83K 301 (22.2) D67N 444 (32.8) 43 (14.3) 0.18 2.7e-12
K219Q 207 (15.3) 11 (3.6) 0.15 4.1e-10
K70R 325 (24.0) 33 (11.0) 0.14 2.9e-8
V118I 230 (16.9) 28 (9.3) 0.11 4.1e-5
F214L 249 (18.4) 32 (10.6) 0.10 5.5e-5
M41L 488 (36.0) 85 (28.2) 0.10 2.2e-4
Continued on facing page
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Associations among reverse transcriptase mutations. An-
other goal of our study was to assess the association of novel
reverse transcriptase mutations with other mutations observed
in the 1,355 NRTI-treated patients, focusing our attention on
those involved in NRTI resistance.
To identify significant patterns of pairwise correlations be-
tween novel mutations and specific reverse transcriptase mu-
tations observed in isolates from RT inhibitor-treated patients,
we calculated the binomial correlation coefficient (phi) and its
statistical significance for each pair of mutations (Table 2).
(i) Novel reverse transcriptase mutations involved in posi-
tive correlations with NRTI resistance mutations. Class I and
class II mutations were positively (phi  0, P  0.0001) cor-
related as pairs with either NAMs 1 (M41L, L210W, and
T215Y) or NAMs 2 (D67N, K70R, and K219Q), both clinically
relevant for their ability to confer cross-resistance to NRTIs
(19) (Table 2). Seven mutations (T39A, K43E, K43N, K43Q,
K122E, E203K, and H208Y) were preferentially correlated as
pairs with several NAMs 1 (Table 2). In particular, the most
frequently selected NAM 1, M41L (prevalence, 36.0%), was
correlated with H208Y (phi  0.28), T39A (phi  0.25), K43E
(phi  0.25), and K43Q (phi  0.22), while L210W (preva-
lence, 21.9%) showed strong pairwise correlations with H208Y
(phi  0.34), K43E (phi  0.33), K43Q (phi  0.28), K122E
(phi  0.22), E203K (phi  0.21), and K43N (phi  0.20).
T215Y (prevalence, 34.2%) was correlated with K43E (phi 
0.24), K43N (phi  0.22), and H208Y (phi  0.21). The seven
mutations that correlated with NAMs 1 were also correlated as
pairs with other NRTI resistance mutations known to occur at
high frequency in combinations with NAMs 1, such as E44D,
V118I, K219N, and K219R (15, 31, 44). In particular, E44D
(prevalence, 9.1%) was strongly correlated with H208Y (phi 
0.35) and E203K (phi  0.27), while V118I (prevalence,
16.9%) was strongly correlated with H208Y (phi  0.28),
K43E (phi  0.26), K43Q (phi  0.24), K122E (phi  0.23),
and E203K (phi  0.22) (Table 2).
On the other hand, D218E was preferentially correlated with
NAMs 2: K219Q (phi  0.34), D67N (phi  0.27), and K70R
(phi  0.23). In addition, D218E was significantly correlated
with L74I (phi  0.23) and T215F (phi  0.18), a mutation at
position 215 that occurs preferentially with NAMs 2. Within
class II mutations, also K20R showed significant pairwise cor-
relations with NAMs 2 and T215F, although less strongly than
those observed with D218E (0.09  phi  0.13; 5.8e-6  P 
1.4e-3) (data not shown).
None of the class I and class II mutations was significantly
correlated with either lamivudine-selected mutation M184V or
tenofovir-selected mutation K65R, thus confirming the low
genetic barrier and the specific pathway towards resistance
against these two drugs. Similarly, no significant associations
were found with the relatively rare multi-NRTI resistance 151
complex (A62V, V75I, F77L, F116Y, and Q151M) or the 69
insertion.
(ii) Novel reverse transcriptase mutations involved in neg-
ative correlations with NRTI resistance mutations. Class III
mutations did not show any positive correlations with NRTI
resistance mutations. In contrast, I50V and R83K showed sig-
nificant negative correlations (phi  0 and P  0.01) with
specific NRTI resistance mutations. In particular, I50V was
negatively associated with the lamivudine-selected mutation
M184V (phi0.07) and R83K showed negative correlations
with NAMs 2 D67N (phi0.18), K219Q (phi0.15), and
K70R (phi  0.14) (Table 2).
(iii) The polymorphism F214L was involved in either posi-
tive or negative correlations with different NRTI resistance
mutations. Even if the frequency of F214L remained stable
(around 18%) in isolates from drug-naı¨ve patients and in both
groups of NRTI-treated patients, however, the F214L muta-
tion showed significant positive correlations with some NAMs
2, such as K219Q (phi  0.25) and K70R (phi  0.24), but no
significant correlation with the NAM 2 D67N (phi  0.04, P 
0.05). In contrast, F214L showed strong negative correlations
with the NAMs 1 T215Y (phi  0.27), M41L (phi  0.23),
and L210W (phi  0.21) and also with E44D (phi  0.10)
(Table 2). Such negative correlation was very strong in all
isolates containing the complete NAM 1 cluster M41L/L210W/
T215Y (phi0.23) (data not shown). In fact, F214L and the
NAM 1 cluster were observed in combination less frequently
than expected under the independence assumption (0.07%
versus 3.7%, P  0.001) (data not shown). On the other hand,
F214L showed positive correlation with the overall NAM 2
cluster D67N/K70R/K219Q (phi  0.18), and the co-occur-
rence was observed significantly more often than expected by
chance (4.5% versus 2.2%, P  0.001, data not shown).
Clusters of correlated mutations. Because pairwise analysis
suggested that most novel mutations are associated with spe-
cific evolutionary pathways of known resistance-conferring mu-
tations, we performed average linkage hierarchical agglomera-
tive cluster analysis (38) to investigate this hypothesis in more
detail.
TABLE 2—Continued
Novel mutation Frequency no. (%)a Correlated mutationb Frequency no. (%)a Covariation frequency (%)c Phi P valued
F214L 249 (18.4) K219Q 207 (15.3) 83 (33.3) 0.25 4.0e-17
K70R 325 (24.0) 117 (47) 0.24 1.6e-16
T215Y 463 (34.2) 9 (1.9) 0.27 1.0e-30
M41L 488 (36.0) 24 (9.6) 0.23 2.9e-20
L210W 297 (21.9) 1 (0.4) 0.21 1.9e-22
E44D 123 (9.1) 3 (1.2) 0.10 2.3e-5
R83K 301 (22.2) 32 (12.8) 0.10 5.5e-5
a The frequency was determined in 1,355 isolates from NRTI-treated patients.
b Positive correlations and negative correlations with phi  0.15 and phi  0.07 are shown, respectively.
c Percentages were calculated for patients containing each specific novel mutation.
d All P values for covariation were significant at a false discovery rate of 0.01 following correction for multiple-hypothesis testing (Benjamini-Hochberg method).
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The dendrogram in Fig. 2 shows that six novel mutations
(T39A, K43E, K43Q, K122E, E203K, and H208Y) grouped
together within a large cluster involving the strong NAM 1
pathway M41L/L210W/T215Y (bootstrap value  1.0). As a
whole, this cluster was highly significant (bootstrap value 
0.89), even though the exact linkage order of these novel mu-
tations is associated with reduced bootstrap values, probably
due to considerable flexibility in the order of accumulation.
Likewise, a strong cluster was formed by NAMs 2 D67N,
K70R, and K219Q (bootstrap value  1.0), to which the al-
ready known mutation T215F and the novel mutations D218E
and F214L were linked as well (bootstrap value  0.95).
Similarly to D218E, K20R also clustered with NAMs 2. The
introduction of K20R did not cause any changes in the topol-
ogy of dendrograms but resulted in reduced confidence values.
In particular, the confidence values for the NAM 1 and
NAM 2 clusters decreased from 0.89 to 0.86 and from 0.95 to
0.86, respectively (data not shown). This drop can be attributed
to the fact that K20R occurred in our data set with both NAMs
1 and NAMs 2 even if much more frequently so in combination
with NAMs 2.
Interestingly, the absence of positive association among class
III mutations with NRTI resistance mutations is also con-
firmed by the cluster analysis. In fact, the topology of the
dendrogram shows that V35I, I50V, and R83K represent an
outgroup (bootstrap value  0.99) distinct from the other
novel reverse transcriptase mutations that cluster with NAMs
1 and NAMs 2 (Fig. 2). In addition, in our data set we could
observe the antagonism of R83K with the complete NAM 2
cluster D67N/K70R/K219Q (phi  0.16), with the co-occur-
rence frequency being significantly lower than that expected by
chance (0.4% versus 2.6%, P  0.001) (data not shown).
Association of novel reverse transcriptase mutations with
viral load and CD4 cell count. A further step in our study was
to assess the association of novel reverse transcriptase muta-
tions with the virologic and immunologic values at the time
of therapeutic failure and genotype test (Table 3). Among
all mutations analyzed, four novel mutations (V35I, K43E,
K122E, and H208Y) were significantly associated with a worse
virologic and immunologic outcome under NRTI failure. In
fact, the presence of at least one of these four mutations in
isolates from NRTI-treated patients was significantly associ-
ated with higher values of viremia and lower CD4 cell counts
(Table 3). In addition, the copresence of K43E and H208Y in
the NAM 1 cluster was also associated at therapeutic failure
with a 3.7-fold increase in viremia (P  0.05; data not shown).
For V35I and K122E this association was also confirmed in
drug-naı¨ve patients (Table 3).
Association of novel mutations with reduced NRTI suscep-
tibility. We showed that some novel mutations (K43E, K122E,
FIG. 2. Dendrogram obtained from average linkage hierarchical agglomerative clustering, showing clusters of known NRTI resistance muta-
tions and novel mutations. The length of branches reflects distances between mutations in the original distance matrix. Bootstrap values, indicating
the significance of clusters, are reported in the boxes. Novel mutations are shown in boldface.
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H208Y, and D218E) were strongly associated and clustered
with known NRTI resistance mutations on divergent evolu-
tionary pathways (NAMs 1 versus NAMs 2). Analyzing se-
quences with known NRTI susceptibility (measured by Virco’s
Antivirogram assay) from the Stanford HIV Drug Resistance
Database, we found that the presence of these mutations at
therapeutic failure was also significantly associated with higher
zidovudine and stavudine resistance (Table 4). In particular,
the presence, individually or combined, of K43E, K122E, and
H208Y with the NAM 1 cluster (M41L/L210W/T215Y) was
associated with a high increase in zidovudine resistance and
also a less extensive increase of stavudine resistance. On the
other hand, the presence of D218E with T215F and the NAM
2 cluster (D67N/K70R/K219Q), with which it has been associ-
ated, determined a 2.5-fold increase of zidovudine resistance
(Table 4).
In contrast, I50V and R83K, which were negatively associ-
ated with NRTI treatment and NRTI resistance mutations,
were associated with increased susceptibility to specific NRTIs
(Table 5). In particular, I50V, which showed antagonism with
the lamivudine-selected mutation M184V, when present to-
gether with M184V determined a 3.5-fold decrease in M184V/
lamivudine resistance. Finally, R83K, which showed antago-
nism with both NAM 1 and NAM 2 clusters, was associated
with a 1.6- to 3.5-fold decrease in both zidovudine and stavu-
dine resistance when present with these mutations.
Location of novel mutations in the three-dimensional struc-
ture of reverse transcriptase. The distribution of novel muta-
tions was found to be widespread in the structure of the en-
zyme involving residues from different subdomains (Fig. 3)
such as finger (amino acids 39, 43, 50, 83, and 122), palm (196,
203, 208, 214, and 218), and template grip (83). Moreover,
these mutated amino acids were generally found at positions
spatially rather distant from NAM residues. In fact, out of the
70 significantly correlated pairs of residues, only 13 (17.3%)
were within 10 Å of each other in the p66 subunit of reverse
TABLE 3. Association of novel reverse transcriptase mutations with viremia and CD4 cell count
Patient group
Mutation Frequencya,
n (%)
Viremia (median)b,
copies/ml Ratio P
c CD4 cell countb
(median), cells/	l Ratio P
c
Position Residue
NRTI treated 35 Vd 942 (69.5) 8,202 340
I 186 (13.7) 16,094 1.9 7.0e-4 278 0.8 9.2e-3
43 Kd 1,188 (87.7) 8,599 332
E 79 (5.8) 27,496 3.2 1.6e-2 307 0.9 0.05
122 Kd 829 (61.2) 8,286 345
E 475 (35.1) 14,340 1.7 2.1e-2* 297 0.8 5.2e-3
208 Hd 1,261 (93.1) 8,414 336
Y 89 (6.6) 38,280 4.5 3.7e-6 202 0.6 1.7e-3
Drug naı¨ve 35 Vd 371 (67.3) 56,290 318
I 124 (22.5) 89,000 1.6 2.0e-2* 183 0.6 4.0e-3
122 Kd 401 (72.8) 53,650 317
E 122 (22.1) 78,420 1.5 2.6e-2* 199 0.6 3.5e-2*
a The frequency was determined in 1,355 NRTI-treated patients and 551 drug-naı¨ve patients.
b Viremia and CD4 cell count values analyzed are concomitant with the genotype resistance testing (30 days) and were available for 90% of samples.
c P values were determined by median test and were corrected for multiple comparison (Benjamini-Hochberg method at a false discovery rate of 0.05). Asterisks
indicate P values not significant at a false discovery rate of 0.05.
d The wild-type amino acid in consensus B.
TABLE 4. Novel reverse transcriptase mutations associated with a decreased NRTI susceptibility
Pattern of mutations No. ofsequencesa
Fold increase in resistanceb (median; IQR)
ZDV d4T 3TC ddI ddC ABC TDF
NAM 1 37 18.0; 7.6–57.3 1.6; 0.7–3.2 3.5; 2.1–8.2 1.4; 1.0–2.4 1.8; 0.8–2.9 3.1; 1.5–6.3 2.1; 1.2–4.2
NAM 1  43E 4 32.6; 13.1–62.9 3.5; 1.9–7.1 3.8; 3.8–3.8 1.0; 0.7–1.2 2.1; 1.1–4.7 3.0; 2.3–3.8 1.8; 1.5–3.2
NAM 1  122E 15 45.0; 20.5–49.0 5.3; 3.1–9.2 9.5; 4.0–16.3 5.5; 3.4–6.6 4.2; 2.7–5.3 10.4; 6.6–12.0 3.3; 3.3–3.3
NAM 1  208Y 4 36.8; 26.5–47.1 3.9; 2.5–6.8 4.0; 3.7–5.5 1.5; 0.9–1.9 0.8; 0.5–1.2 6.4; 6.4–6.4 2.7; 2.1–3.4
NAM 1  43E 
122E  208Yc
3 886.3; 648.1–1,077.7 3.5; 3.1–4.6 9.9; 9.9–9.9 2.1; 1.5–2.9 1.3; 1.1–2.4 3.8; 3.3–4.8 NA
NAM 2 11 5.6; 3.2–8.2 1.0; 0.6–1.2 4.4; 4.4–4.4 1.4; 0.9–2.1 2.1; 1.8–2.8 2.3; 1.2–3.7 1.2; 0.8–1.8
NAM 2  215F 8 12.5; 8.4–13.8 1.2; 0.7–1.3 2.2; 1.2–3.3 0.9; 0.7–1.6 0.8; 0.5–1.9 2.7; 1.6–5.7 1.6; 1.4–2.3
NAM 2  218E 9 4.5; 1.8–13.4 1.2; 1.0–2.6 1.2; 1.0–19.8 1.0; 0.7–1.4 1.0; 0.8–3.6 2.8; 1.9–3. 2.7; 0.7–3.1
NAM 2  214L 2 8.5; 7.8–9.3 0.7; 0.6–1.1 NA 0.8; 0.7–0.9 0.5; 0.5–0.7 1.6; 1.2–2.0 1.5; 1.2–1.8
NAM 2  215F 
218Ed
3 30.9; 16.2–75.9 1.9; 0.4–3.4 13.2; 13.2–13.2 1.4; 0.8–1.9 2.1; 1.7–2.2 5.5; 1.3–10.9 0.7; 0.6–5.9
a Sequences were collected from the Stanford HIV Drug Resistance Database (http://hivdb.stanford.edu).
b The values for increases in resistance (n-fold) are derived from the real phenotypic data measured by Virco’s Antivirogram assay. Abbreviations: ZDV, zidovudine;
d4T, stavudine; 3TC, lamivudine; ddI, didanosine; ddC, zalcitabine; ABC, abacavir; TDF, tenofovir; IQR, interquartile range; NA, not available.
c Present also with D67NE44DV118IK219N and E203K and R211K.
d Present also with M41L and K43E.
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transcriptase, three of which were contiguous in primary se-
quence. Nonetheless, only for one of these (43-44) was it pos-
sible to establish the possibility of a direct interaction between
their side chains (data not shown).
DISCUSSION
Our study suggests that other HIV-1 reverse transcriptase
mutations, beyond the currently known NRTI resistance mu-
tations, may contribute to the evolution of NRTI resistance in
vivo. In fact, 16 novel mutations have been identified, charac-
terized, and grouped into distinct classes.
Class I mutations (K43E/N/Q, E203D/K, H208Y, and
D218E) were rare or completely absent in isolates from drug-
naı¨ve patients. In contrast, their frequency significantly in-
creased in isolates from patients failing an antiretroviral regi-
men containing at least one NRTI, thus suggesting that these
mutations may require the NRTI selective pressure for their
emergence at virological failure. Moreover, class I mutations
occurred principally in combination with several NRTI resis-
tance mutations, suggesting that they emerge after a prolonged
NRTI exposure when the virus has already accumulated a large
number of NRTI resistance mutations. As a confirmation of
this hypothesis, a previous study already demonstrated that the
emergence of H208Y mutation may require as a prerequisite
the presence of at least M41L and T215Y (40).
Class II mutations (K20R, V35M, T39A, K122E, and
G196E) were already present in isolates from drug-naı¨ve pa-
tients, but their frequency significantly increased in isolates
from patients failing an antiretroviral regimen containing at
least one NRTI, thus suggesting a positive association of these
mutations with NRTI treatment.
These results are consistent with recent analyses conducted
with a large number of reverse transcriptase sequences (13, 30,
32), which provide strong evidence for an “extended spectrum”
of reverse transcriptase mutations associated with multi-NRTI
treatment. The few discordances in the number and prevalence
of new treatment-associated mutated positions that we ob-
served, compared with the studies mentioned above, may
probably be related to the different number of patients an-
alyzed, the patients’ characteristics, and the therapeutic reg-
imens used.
Interestingly, two mutations (T39A and K122E) were also
associated with drug resistance and/or positive selection pres-
sure in another study (8), based on ratios of nonsynonymous to
synonymous mutations (Ka/Ks) of1 similar to those observed
for the already-known RTI resistance mutations.
Moreover, all novel mutations, with the exception of one
(R83K), correspond with changes in known HLA-restricted
cytotoxic T-lymphocyte epitopes in reverse transcriptase (HIV
Molecular Immunology Database, http://www.hiv.lanl.gov).
Further studies should examine the interactions between these
novel mutations (together with the other NRTI mutations) and
putative cytotoxic T-lymphocyte escape mutations to better
understand synergistic and/or antagonistic interactions be-
tween immune pressure and drug pressure.
Furthermore, class I and class II mutations established ag-
onistic interactions with the currently known NRTI resistance
mutations (both in pairs and in clusters). In particular, for the
mutations T39A, K43E/Q, E203K, K122E, and H208Y the
FIG. 3. Localization of novel mutations in the structure of HIV-1
RT. The structure of HIV-1 RT in the region near the polymerase
active site is shown. The subdomains are color coded (palm, magenta;
thumb, green; fingers, blue). NAMs 1 are in salmon and NAMs 2 in
cyan; NNRTI resistance mutations are in blue and novel mutations in
yellow; other RT inhibitor resistance mutations are in green.
TABLE 5. Novel reverse transcriptase mutations associated with an
increased NRTI susceptibilitya
Drug and pattern
of mutations
No. of
sequencesb
Median fold increase
in resistance c (IQR) Ratio
ZDV
NAM 1  83Rd 101 15.5 (4.1–48)
NAM 1  83K 19 9.6 (4.3–35.5) 1.6
NAM 2  83Rd,f 61 5.6 (2.1–12)
NAM 2  83Kf 5 1.6 (1.5–3.7) 3.5
D4T
NAM 1  83Rd 83 1.7 (0.9–3.9)
NAM 1  83K 19 0.8 (0.8–1.2) 2.1e
NAM 2  83Rd,f 60 1.2 (0.7–2.1)
NAM 2  83Kf 6 0.7 (0.5–0.9) 1.7
3TC
M184V  50Id 101 81.7 (43.3–90.5)
M184V  50V 1 23.6 3.5
a Abbreviations: ZDV, zidovudine; d4T, stavudine; 3TC, lamivudine; IQR,
interquartile range.
b Sequences were collected from the Stanford HIV Drug Resistance Database
(http://hivdb.stanford.edu).
c The values for increase in resistance are derived from the real phenotypic
data measured by Virco’s Antivirogram assay.
d Indicates the wild-type amino acid in consensus B.
e The difference in the increase in stavudine resistance is statistically significant
(P  0.018; median test).
f For the absence of sequences with 83K and NAMs 2 (D67N/K70R/K219Q),
the sequences selected contained at least one NAM 2.
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agonistic interactions principally involved the NAM 1 pathway
(M41L, L210W, T215Y, E44D, V118I, and K219R), thus sug-
gesting that these mutations may contribute to NAM 1-medi-
ated resistance to NRTIs. The strong agonistic interactions
that we observed between the NAM 1 M41L and either T39A
or K43E/Q, as well as that between the NAM 1 L210W and
H208Y, could be related to the fact that these residues are
located at the C terminus of an alpha-helix so that the corre-
lated mutation probably contributes to a greater stabilization
of this secondary structure element. This can be important for
enzymatic activity as all of these residues are located close to
the binding site of the incoming nucleotide.
On the other hand, two mutations (D218E and K20R) were
associated with the NAM 2 pathway (D67N, K70R, K219Q,
and T215F). As D218E was significantly associated with the
use of zidovudine, and its presence in the NAM 2 cluster
determined a 2.5-fold increase in zidovudine resistance, we
suggest that this mutation may contribute to NAM 2-mediated
resistance to zidovudine. This hypothesis is consistent with
results from a recent study which showed that a prolonged
exposure to zidovudine is associated with an increased proba-
bility of observing the NAM 2 profile (A. Cozzi-Lepri, L. Ruiz,
C. Loveday, A. N. Phillips, B. Clotet, P. Reiss, and J. D.
Lundgren, Abstr. 12th Conf. Retrovir. Opportunistic Infect.,
abstr. 708, 2005).
While our results provide strong evidence that additional
reverse transcriptase mutations are preferentially associated
with one of the classical NAM pathways, we emphasize that
this association is not exclusive, not even among the core
patterns M41LL210WY215Y and D67NK70RK219Q.
In fact, a recent study (D. T. Dunn, Abstr. 14th HIV Drug
Resist. Int. Workshop, abstr. 130, 2005) has found 116 distinct
NAM patterns in a set of 2,379 sequences, and 40% of these
sequences contained mutations from both pathways, with
D67N accounting for most of the “crossover” between the
groups. These “fuzzy,” rather than rigid, covariation patterns
can be summarized and visualized via principal component
analysis (13) or multidimensional scaling (38), for example.
In the light of the observed NAM pattern diversity, it is
reasonable to expect that the frequency of a given pattern is
correlated with replication parameters associated with the pat-
tern. Indeed, as an example, the antagonistic covariation be-
tween NAM 1 M41L and NAM 2 K70R is paralleled by a
marked replicative defect characterizing viral strains with those
two mutations (15, 18, 44).
The fact that the copresence of K43E, K122E, or H208Y
alone or as a cluster with the NAMs 1 was associated with
higher viremia and lower CD4 cell count at therapeutic failure
may suggest a compensatory role of these mutations, leading to
improved viral replication, especially if the response is com-
promised by the presence of other NRTI resistance mutations,
such as NAMs 1.
It is also conceivable that class I and class II mutations
contribute to a further increase in the level of resistance. Phe-
notypic resistance data in the Stanford HIV Drug Resistance
Database support this hypothesis. In particular, we observed that
some class I and II mutations at therapeutic failure were able to
affect NRTI susceptibility in vitro (Stanford HIV Drug Resistance
Database, http://hivdb.Stanford.edu). The presence—individually
or combined—of K43E, K122E and H208Y, with and without
NAMs 1, was associated with a high increase in zidovudine
resistance. In addition, on an independent data set, feature
ranking based on support vector machines and matched geno-
type-phenotype pairs indicated that six novel mutations (H208Y,
K122E, T39A, K43E, E203K, and D218E) are prominently
(within the top 20 mutations) involved in determining zidovu-
dine resistance, ranking even above several of the classical
zidovudine mutations (H208Y, K122E, T39A, K43E  T215F,
K219Q, and K70R) (38).
The H208Y mutation, frequently selected in combination
with the NAM pathway under combined therapy with zidovu-
dine and lamivudine, was recently shown to be associated with
an increase in the level of zidovudine resistance (32, 39, 40). It
is known that the lamivudine-selected mutation M184V de-
creases the ability of HIV-1 reverse transcriptase to carry out
ATP-mediated removal of zidovudine or stavudine monophos-
phate from the terminated cDNA chain; thus, it was supposed
that the appearance of H208Y, proximal to the ATP binding
site, may influence the geometry of the ATP binding site,
maintaining the efficiency of the excision reaction even in the
presence of M184V (34).
Moreover, the H208Y mutation was recently associated with
resistance to foscarnet, a phosphonoformate that competes
with the pyrophosphates (PPi) for the hydrolytic removal of the
chain-terminating NRTI (23). Overall, our data support the
idea that H208Y may play a role in mechanisms that regulate
NRTI resistance, presumably by promoting the primer rescue.
Interestingly, our covariation analysis showed that different
mutations at the same position showed differential clustering.
In fact, both hierarchical clustering (Fig. 2) and a multidimen-
sional scaling analysis (38) are consistent with previous studies
of the differential behavior of mutation T215F versus T215Y
and K219Q versus K219R. In fact, mutagenesis studies in com-
bination with growth competition assays showed that viral
strains with the mutation T215F had a lower replicative capac-
ity than the T215Y variant in the presence of M41L and
L210W (Z. X. Hu, P. Reid, H. Hatano, J. Lu, and Kuritzkes,
Abstr. 13th Int. HIV Drug Resist. Workshop, abstr. 59, 2004).
Thus, the phenotypic impact of T215F, which is positive in the
presence of NAMs 2 and negative in the presence of NAMs 1,
seems to be dependent on the genomic background in which
the mutation occurs. This may have important implications for
resistance prediction systems. In fact, prediction systems based
on linear models cannot accommodate situations such as these,
in which the effect of a mutation or mutational pattern is
dependent on the genomic background in which it occurs, in
contrast to nonlinear methods (12, 46) or tree- or rules-based
approaches (4, 37).
Taken together, our data suggest that class I and class II
mutations may actively participate in the regulation of NRTI
resistance. Moreover, our data also indicate that despite an
obvious preference for certain mutational patterns, the accu-
mulation order of the novel mutations is also characterized by
considerable flexibility (T. Sing, V. Svicher, N. Beerenwinkel,
F. Ceccherini-Silberstein, I. Savenkov, K. Korn, C. F. Perno, H.
Walter, and T. Lengauer, Abstr. 14th Int. HIV Drug Resist.
Workshop, abstr. 50, 2005).
Differently from the other mutations, class III mutations
(I35V, I50V, and R83K) are polymorphisms in isolates from
drug-naı¨ve patients, and their frequency decreased in isolates
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from patients who failed an antiretroviral regimen containing
at least one NRTI. Moreover, class III mutations were rarely
found in the presence of NRTI resistance mutations and were
never positively associated with any NRTI resistance muta-
tions, thus suggesting the negative association of these mutations
with NRTI treatment and failure. If anything, I50V and R83K
were involved in antagonistic interactions with NRTI resistance
mutations (M184V and NAMs, respectively) and were then as-
sociated, when rarely present with M184V or NAMs, respectively,
with increased susceptibility to lamivudine and thymidine ana-
logues, respectively. It is conceivable that these mutations are
selectively neutral in wild-type strains but weakly deleterious in
terms of viral replication in the presence of NRTI resistance
mutations, thus contributing to increases in the level of the
genetic barrier to NRTI resistance. However, this hypothe-
sis needs confirmation from both in vitro studies and clinical
practice.
We also analyzed the F214L polymorphism that is charac-
terized by an inconspicuous prevalence behavior, with virtually
constant frequency in naı¨ve and NRTI-failing patients.
Surprisingly, our covariation analysis identified an agonistic
interaction of the L variant with the NAM 2 pathway, whereas
the more common F variant established an agonistic interac-
tion with the NAM 1 cluster. These results are consistent with
recent studies in which it was supposed that the F variant,
specifically associated with the NAM 1 profile (40), may im-
prove the efficacy of the ATP-mediated removal of the zidovu-
dine or stavudine monophosphate from the terminated cDNA
chain (34). It is conceivable that position 214 remains stable
during NRTI exposure and that the particular residue found in
the dominant quasispecies at position 214 before therapy onset
may represent one of the determinants for NAM pathway
choice. Thus, we suggest that NAM pathway choice is deter-
mined not only by chance effects, or host factors such as HLA
genotype (19), but also by the genomic background of the
treatment-naı¨ve viral population. Together with the observa-
tion that the NAM 1 group exerts stronger zidovudine resis-
tance (38) and clinical cross-resistance to tenofovir than NAMs
2 (25), baseline genotypic testing and subsequent therapy
choice might benefit from taking into account positions such as
214 as possible determinants of the future course of resistance
evolution.
It should be noted that all patients analyzed in this study
carried the HIV-1 subtype B. Further studies should also in-
vestigate the prevalence and the role of the novel mutations in
other non-B subtypes. In fact, it is known that pathways of viral
evolution toward drug resistance may proceed through distinct
steps and at different rates among different HIV-1 subtypes
(45). Moreover, we cannot exclude the possibility that the
observed patterns of correlated mutations may be the result of
pharmacological pressure imposed by the drug regimens that
were used by our cohort, while other treatment regimens may
lead to the development of pathways which are partly different
from those that we observed. Further analyses of expanded
databases (with genotypic and clinical and/or phenotypic data)
complemented by specific experimental verification will pro-
vide insights regarding these important open questions and will
give more information on the impact of these mutations on
virus replication and drug resistance. In particular, further
studies using sequences of the entire reverse transcriptase/
RNase H are also necessary. In fact, the exclusion of the
RNase H domain from our study represents a limitation, since
recent data show that mutations in RNase H were associated with
the presence of NRTI mutations and may also enhance resistance
to NRTIs in vitro (27; A. G. Marcelin, B. Roquebert, I. Malet, M.
Wirden, A. Simon, C. Katlama, and V. Calvez, Abstr. 14th Int.
HIV Drug Resist. Workshop, abstr. 50, 2005).
In conclusion, our study reinforces the complexity of NRTI
resistance and contributes to a better definition of the reverse
transcriptase mutational patterns involved in regulating resis-
tance to NRTIs. It suggests that other mutations beyond those
currently known to confer resistance may regulate, not only
positively but also negatively, this highly complex network. On
this basis, novel mutations should be taken into account to
define improved algorithms for predicting phenotypic resis-
tance or clinical response to antiretroviral drugs.
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